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Short QT Syndrome is Highly Lethal 
 A total of 62 out of 73 short QT syndrome (SQTS) 
patients (84% male; mean age, 26 ± 15 years; corrected QT 
interval, 329 ± 22 ms) were followed for 60 ± 41 months. 
Cardiac arrest (CA) was the most frequent presenting 
symptom (40% of probands). There was an age 
dependency in the susceptibility to arrhythmias, with a 
peak in the occurrence of CA in the first year of life (4%) 
and a second peak (1.3%) between 20 and 40 years of age; 
the probability of a first occurrence of CA by 40 years of 
age was 41%. Despite the male predominance, female 
patients had a similar risk profile. Familial disease was 
present in 44% of kindreds, but the yield of genetic 
screening was low (14%). A history of CA was the only 
predictor of recurrences at follow-up (p< 0.0000001). 
Arrhythmias occurred mainly at rest. The authors 
concluded that SQTS is highly lethal with CA often as the 
first manifestation of the disease with a peak incidence in 
the first year of life; survivors of CA have a high CA 
recurrence rate; implantation of a defibrillator is strongly 
recommended (Mazzanti A et al, J Am Coll Cardiol 
2014;63:1300-1308). 
 
Inferior Vena Cava (IVC) Filters in Patients With 
Acute Symptomatic Venous Thromboembolism (VTE) 
and a Significant Bleeding Risk Lower Pulmonary 
Embolism Mortality but Increase Risk of Recurrence 
 In a prospective cohort study of patients with acute 
VTE identified from the RIETE (Computerized Registry 
of Patients With Venous Thromboembolism), the 
investigators assessed the association between IVC filter 
insertion due to significant bleeding risk and the 30-day 
outcomes [all-cause mortality, pulmonary embolism (PE)-
related mortality, and VTE rates]. Of 40,142 patients who 
had acute symptomatic VTE, 371 received an IVC filter. A 
total of 344 patients treated with a filter were matched with 
344 patients treated without a filter. There was a non-
significant trend toward lower risk of all-cause death for 
filter insertion (6.6% vs 10.2%; p = 0.12). The risk adjusted 
PE-related mortality rate was lower for filter insertion than 
no insertion (1.7% vs 4.9%; p = 0.03). Risk-adjusted 
recurrent VTE rates were higher for filter insertion than for 
no insertion (6.1% vs 0.6%; p < 0.001). The authors 
concluded that in patients presenting with VTE and a 
significant bleeding risk, IVC filter insertion compared 
with anticoagulant therapy was associated with a lower 
risk of PE-related death and a higher risk of recurrent VTE 
(Muriel et al, J Am Coll Cardiol 2014;63:1675–1683).  
 
Three-Year Follow-up of CONFIRM trial: FIRM-
Guided Ablation is More Effective than Conventional 
Ablation Alone at Preventing AF Recurrences 
 
 Source (focal impulse and rotor modulation [FIRM]) 
ablation (n= 27) was compared with conventional ablation 
(pulmonary vein isolation-PVI) (n=65) of atrial fibrillation 
(AF). FIRM mapping revealed a median of 2 rotors or 
focal sources in 97.7% of patients during AF. At 3 years, 
patients receiving FIRM-guided ablation, compared to 
FIRM blinded therapy, maintained higher freedom from 
AF after 1.2+0.4 procedures (median 1) (77.8% vs 38.5%, 
p = 0.001) and a single procedure (p < 0.001) and higher 
freedom from all atrial arrhythmias (p = 0.003). The 
authors concluded that FIRM-guided ablation is more 
durable than conventional trigger-based ablation in 
preventing 3-year AF recurrence (Narayan et al, J Am Coll 
Cardiol 2014;63:1761–1768).  
 
Successful Catheter Ablation of Atrial Fibrillation 
(AF) May Last a Decade in the Majority of Patients 
 A prospectively identified group of 445 patients who 
demonstrated freedom from AF for at least 1 year post-
ablation (single procedure in 87.9%) was followed for 66.0 
± 34.0 months. At 40.7 ± 27.0 months postablation, 97 
(21.8%) patients experienced at least 1 episode of recurrent 
AF. The majority of events were symptomatic. There was 
a steady attrition rate reaching 16.3% at 5 years and 29.8% 
at 10 years. In 29 patients (29.5%) recurrences were self-
limited; the remainder required either medical therapy or 
repeat ablation. By multivariate analysis, persistent AF 
(hazard ratio-HR 3.08; P < 0.0001) and hypertension (HR 
1.08; P = 0.009) were independent risk factors for the 
recurrence of AF; presence of both factors led to 
recurrence in 37.6% at 5 years and 68.8% at 10 years. The 
authors concluded that at 10 years after a successful 
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ablation of AF, most patients continue to demonstrate 
freedom from AF. Hypertension and prior persistent AF 
predict recurrences (Steinberg et al, Heart Rhythm 
2014;11:771-776).  
 
EMBRACE: 30-Day Event – Triggered Recorder 
Better Detects Atrial Fibrillation in Patients with 
Cryptogenic Stroke 
 A total of 572 patients >55 years of age, without known 
atrial fibrillation (AF), who had had a cryptogenic 
ischemic stroke or transient ischemic attack (TIA) within 
the previous 6 months were randomly assigned to undergo 
ambulatory ECG monitoring with either a 30-day event-
triggered recorder or a conventional 24-hour monitor. AF 
lasting >30 s was detected in 16.1% in the event recorder 
group vs 3.2% in the control group (P<0.001; number 
needed to screen, 8). AF lasting >2.5 min was present in 
9.9% in the longer monitored group vs 2.5% in the control 
group (P<0.001). By 90 days, oral anticoagulant therapy 
had been prescribed for more patients in the event monitor 
group than in the control group (18.6% vs 11.1%; P=0.01). 
The authors concluded that among patients with a recent 
cryptogenic stroke or TIA >55 years of age, paroxysmal 
AF was common. Noninvasive ambulatory ECG 
monitoring for 30 days significantly improved the 
detection of AF by a factor of >5 and nearly doubled the 
rate of anticoagulant treatment (Gladstone et al, N Engl J 
Med 2014; 370:2467-2477).  
 
CRYSTAL AF: Insertable Loop Monitor Better 
Detects Atrial Fibrillation (AF) in Patients With 
Cryptogenic Stroke  
 A total of 441 patients (>40 years old) with cryptogenic 
stroke were randomized to an insertable cardiac monitor 
(ICM) or conventional follow-up to assess detection of AF. 
By 6 months, AF was detected in 8.9% of patients in the 
ICM group (19 patients) vs 1.4% of patients in the control 
group (3 patients) (hazard ratio, 6.4; P<0.001). By 12 
months, AF was detected in 12.4% of patients in the ICM 
group (29 patients) vs 2.0% of patients in the control group 
(4 patients) (hazard ratio, 7.3; P<0.001). The authors 
concluded that ECG monitoring with an ICM was superior 
to conventional follow-up for detecting AF after 
cryptogenic stroke (Sanna et al, N Engl J Med 2014; 
370:2478-2486).  
 
Pharmacologic Rate- and Rhythm-Control Therapies 
are Comparable, but Ablation is Better in Patients 
With Atrial Fibrillation 
 A total of 200 articles (162 studies) involving 28 836 
patients were reviewed comparing rate- and rhythm-
control strategies. Strength of evidence (SOE) was 
moderate supporting comparable efficacy with regard to 
all-cause mortality (odds ratio-OR, 1.34), cardiac mortality 
(OR, 0.96), and stroke (OR, 0.99) in older patients with 
mild AF symptoms. For rhythm-control therapies in 
reducing AF recurrence, SOE was high favoring 
pulmonary vein isolation vs antiarrhythmic drugs (OR, 
5.87) and the surgical maze procedure done during other 
cardiac surgery vs other cardiac surgery alone (OR, 7.94). 
The authors concluded that pharmacologic rate- and 
rhythm-control strategies have comparable efficacy in 
older patients with mild AF symptoms. Pulmonary vein 
isolation is better than antiarrhythmic medications at 
reducing recurrences of AF in younger patients with 
paroxysmal AF and mild structural heart disease (Al-
Khatib et al, Ann Intern Med. 2014;160:760-773).  
 
Colchicine May Reduce One-Year Postablation AF 
Recurrence 
 Among patients with paroxysmal atrial fibrillation (AF) 
who had a single ablation, those who then received a short 
course of colchicine were less likely to have AF recurrence 
and more likely to have higher quality of life a year later, 
researchers report. The mid-term results from the current 
study were impressive. Only 6 patients needed to be treated 
to avoid one AF recurrence. The generic drug colchicine—
used for a long time, is approved for gout and familial 
Mediterranean fever, and has been studied for resistant 
pericarditis—"seems to be a rather simple and powerful 
approach to reducing subsequent effects" in people with 
paroxysmal AF. The study showed that colchicine "is a 
durable, long-lasting, preventive measure associated with 
isolated pulmonary vein ablation”. What's really incredible 
is that it's a really cheap addition to a very expensive 
procedure. According to current consensus, the first 3 
months after ablation is considered a "blanking" period—
that is, any AF or atrial flutter during this time is 
considered "early recurrence" and is not considered as part 
of "AF recurrence." The researchers hypothesized that 
colchicine might help reduce inflammation after ablation 
and thus decrease AF recurrence. In fact, an earlier study 
did demonstrate "proof of principle". There was a 
significant reduction in the incidence of early AF 
recurrence and smaller increases in the proinflammatory 
biomarkers C-reactive protein (CRP) and interleukin-6 
(IL-6) in patients who had received colchicine compared 
with those who received placebo after ablation for AF. The 
primary outcome in the current study was efficacy at 12 
months after the blanking period. The secondary outcome 
was change in scores for physical and psychological health 
in the World Health Organization Quality of Life scale at 
3 and 12 months compared with baseline. The researchers 
analyzed data from 206 patients with paroxysmal AF who 
were seen in 3 centers in Europe and randomized to 
undergo pulmonary vein isolation followed by 0.5-mg 
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colchicine bid for 3 months or placebo. The patients were 
younger than 80 (with a mean age of 62.2), and 70% were 
men. They had no severe liver or kidney disease, since 
about 80% of the drug is metabolized in the liver and about 
20% is excreted in the urine. Each patient had an average 
of 13.8 Holter recordings. After a median of 15 months, 32 
of 103 patients (31.1%) in the colchicine group vs 51 of 
103 patients (49.5%) in the control group had AF 
recurrence (p=0.01), a 37% reduction in relative risk. 
These significant differences were seen even when the 
blanking period was not excluded. Most recurrences 
occurred within the first 6 months after ablation. CRP and 
IL-6 levels were strongly associated with subsequent 
recurrences. Diarrhea and nausea were the most frequently 
reported adverse events. Diarrhea was reported in 10 of 
103 patients (9.7%) in the treatment group vs 2 of 103 
patients (1.9%) in the control group. However, only 5 cases 
in the colchicine group and one case in the control group 
lasted more than one week. Nausea was reported by 6 
patients taking colchicine (5.8%) vs 3 patients taking 
placebo (2.9%). Physical- and psychological-health 
quality-of-life scores increased in both groups, but the 
improvement was greater in the patients who had received 
colchicine. On the whole, colchicine has a potent anti-
inflammatory effect, and, even more important, it is 
probably the only medication with anti-inflammatory 
action that can be used safely for a relatively long period 
of time in patients with cardiovascular disease, given the 
well-known and feared cardiovascular adverse effects of 
other anti-inflammatory classes, including corticosteroids 
and nonsteroidal anti-inflammatory drugs. Before this use 
of colchicine becomes part of clinical practice, funding is 
needed to conduct further studies to determine the optimal 
dose and length of treatment and to conduct a large-scale 
clinical trial that could lead to regulatory approval 
(Deftereos et al, Heart Rhythm 2014;11:620-628).  
 
Athlete-Specific ECG Criteria Proposed for Sports 
Screening 
 The current study, presented at the Heart Rhythm 
Society-HRS 2014 Scientific Sessions, suggests that the 
history and physical may not be that good for picking up 
abnormalities that could put these athletes at risk of sudden 
death. We need to be looking at further screening methods 
such as an ECG to determine what best way to prevent 
sudden death in these young people. In the current study, 
4812 teenaged athletes were screened at US high schools 
from October 2010 through June 2013. All completed a 
questionnaire with personal and family history screening 
questions like those recommended by the AHA and 
underwent 12-lead ECG, with additional 
echocardiography for anyone with an abnormality in the 
other tests. The ESC criteria for interpreting ECGs of 
athletes were used for the first two-thirds of the cohort and 
the Seattle criteria for the latter one-third. Women made up 
46% of the group; 65% were white, 10% Asian, and 6% 
were African American. The screening process identified 
"significant abnormalities requiring further evaluation" in 
23 of the subjects, or about 0.5% of the cohort; they 
included 9 cases of Wolff-Parkinson-White syndrome, 4 
anomalous coronary arteries, 3 dilated aortic roots or 
aneurysms, 3 long-QT syndromes, 2 of hypertrophic 
cardiomyopathies, one with ventricular arrhythmia, and 
one with short-QT syndrome. An abnormal history or 
physical pointed to the diagnoses in 61% of cases and an 
abnormal ECG in 70%. The rate of false-positive 
diagnoses was 50% for the initial history and physical 
(which improved to 32% after physician review), 4% for 
the ECG, and 35% for the postreview history and physical 
considered with the ECG. Abnormalities pointing to 
possibly increased sudden-death risk in the Seattle criteria 
include: 
 T-wave inversion (defined as >1 mm in depth in >2 
leads V2-V6, II and aVF, or I and aVL). 
 Long QT interval (corrected QT-QTc >470 ms in men, 
>480 ms in women). 
 Short QT interval (QTc <320 ms). 
 ST-segment depression (>0.5 mm in >2 leads). 
 Pathologic Q waves (>3 mm in depth or >40 ms in 
duration in >2 leads, excluding III and aVR). 
 Left atrial enlargement (P-wave duration >120 ms in 
leads I or II with negative portion of the P wave >1 mm 
in depth and >40 ms in duration in lead V1). 
 Right ventricular hypertrophy (R-V1+ S-V5 >10.5 mm 
plus right axis deviation >120°). 
 Compete LBBB or any QRS >140 ms. 
 Mobitz type II 2° AV block or complete heart block. 
 Ventricular preexcitation (PR interval <120 ms with a 
delta wave and QRS >120 ms). 
 Profound sinus bradycardia defined as <30 beats per 
minute or sinus pauses >3 s. 
 Atrial tachyarrhythmias (supraventricular tachycardia 
or atrial fibrillation or flutter). 
 PVCs (>2 per 10-sec tracing), ventricular arrhythmias 
(couplets, nonsustained VT). 
 Type 1 Brugada pattern. 
(HRS 2014 Scientific Sessions; Abstract PO01-194). 
 
COMPARE Trial: Performing Catheter Ablation for 
AF Without Warfarin Discontinuation Reduces 
Occurrence of Stroke and/or Minor Bleeding When 
Compared to Bridging With Heparin 
 The "COMPARE" Randomized Trial is the first 
randomized study showing that performing catheter 
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ablation of AF without warfarin discontinuation reduces 
the occurrence of peri-procedural stroke and minor 
bleeding complications when compared to bridging with 
low molecular weight heparin (LMWH). “COMPARE” 
was a prospective, randomized, parallel-group, multicenter 
study assessing the role of continuous warfarin therapy in 
preventing periprocedural thromboembolic (TE) events 
after radiofrequency catheter ablation. Inclusion criteria 
were: age 18 or above, INR in the range of 2.0-3.0 in the 
last 3-4 weeks prior to ablation and CHADS2 score >1 or 
CHADS score=1. A total of 1584 patients were randomly 
assigned (1:1 ratio) to anticoagulation strategy of either 
discontinued warfarin (group I) or continuous warfarin 
(group II). Periprocedural symptomatic TE events 
occurred in 39 (4.9%) patients in group I [29(3.7%) stroke 
and 10 (1.3%) TIA] and only in 2 (0.25%) patients (both 
stroke) in group II (p <0.001). Compared to group I, 
patients in group II had significantly lower risk for 
periprocedural TE; the unadjusted relative risk was 0.051, 
with a relative risk reduction of 95% in favor of the 
uninterrupted warfarin. Eighty-five percent of all the TE 
events (35/41) occurred in the long standing-persistent 
(LSP) AF population. In the off warfarin population (group 
I), one TIA and one stroke were reported in PAF, 2 TIAs 
and 2 strokes in persistent AF patients, while 7 TIAs and 
26 strokes were reported in LSP AF patients. In group II 
patients, both events occurred in LSP AF patients. Both 
patients had subtherapeutic INR the day of the procedure 
(1.6 and 1.7 respectively). Both patients had a TEE that did 
not show thrombus and did not receive LMWH. 
Significant reduction in TE risk in the “on” warfarin group, 
as compared to the “off”  warfarin, was consistently 
observed across 6 major subgroups- female gender, age 
>75 years, diabetes, coronary artery disease, and prior 
history of cerebrovascular accident (CVA) and or /TIA, 
and CHADS2 score. No statistical differences between 
groups were found for major bleeding. Although not 
statistically different, group II (on warfarin) had a relative 
risk reduction for major bleedings of 50% when compared 
to group I (off warfarin). Of great clinical interest is the 
fact that in case of tamponade no major differences in the 
patients’ management were found between groups with the 
exception of more fluid aspirated and more protamine 
utilized in group II. In group II, besides protamine to 
reverse the effect of i.v. heparin, fresh frozen plasma was 
necessary to reverse the effect of warfarin. Minor bleeding 
complications were significantly higher in the off warfarin 
group. Of note is the fact that all procedures were 
performed under intracardiac echo (ICE) guidance. The 
use of ICE could help reducing bleeding complication, in 
addition to facilitate transseptal access, confirm ablation 
catheter contact and improve anatomical orientation (Di 
Biase et al, Circulation 2014;129:2638-2644).  
 
Predicting Coronary Plaque Rupture 
 The “napkin-ring sign”, a feature seen on coronary 
computed-tomography angiography (CCTA) can help 
identify coronary plaques at risk of rupture. In Nature 
Reviews Cardiology, Dr Pál Maurovich-Horvat and 
colleagues argue that there is a role for CCTA that goes 
beyond ruling out coronary stenosis. Some of the CCTA 
plaque features are more important than others to identify 
high-risk plaques and to predict adverse cardiovascular 
events. Low CT attenuation, positive remodeling, and the 
napkin-ring sign indicate a 5- to 20-fold increase in the risk 
of suffering acute coronary syndrome (ACS). To further 
improve the prognostic value of CCTA to identify high-
risk plaques, however, it is necessary to combine different 
quantitative and qualitative plaque characteristics—for 
example, plaque volume and napkin-ring sign—with 
functional information, such as fractional flow reserve 
(FFR) or endothelial shear stress, or preventive therapies 
based on patient-specific information. Large plaque 
burden with high-risk features might warrant intensified 
statin therapy. Combining functional and morphological 
features could lead to a vulnerable plaque score that could 
help predict the likelihood of plaque rupture and sudden 
luminal thrombosis (Maurovich-Horvat et al, Nat Rev 
Cardiol 2014; DOI:10.1038/nrcardio.2014.60. Epub 2014 
Apr 22). 
 
Prophylactic Implantable Cardioverter-Defibrillators 
(ICDs) Confer Improved Survival in Patients With Left 
Ventricular Ejection Fraction (LVEF) Between 30% 
and 35% 
 A retrospective cohort study of Medicare beneficiaries 
in the National Cardiovascular Data Registry ICD registry 
compared 3120 patients with an LVEF between 30% and 
35% (816 in matched cohorts) who received an ICD during 
a heart failure hospitalization with similar patients with no 
ICD. The analysis was repeated for 4578 patients (2176 in 
matched cohorts) with an LVEF <30%. There were no 
significant differences in the baseline characteristics of the 
matched groups (n = 408 for both groups). Among patients 
with an LVEF between 30% and 35%, there were 248 
deaths in the ICD Registry group, within a median follow-
up of 4.4 years and 249 deaths in the control group, within 
a median follow-up of 2.9 years. The risk of all-cause 
mortality in patients with an LVEF between 30% and 35% 
and an ICD was significantly lower than that in matched 
patients without an ICD (3-year mortality rates: 51.4% vs 
55.0%; hazard ratio-HR, 0.83; P =0 .04). Presence of an 
ICD also was associated with better survival in patients 
with an LVEF <30% (3-year mortality rates: 45% vs 
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57.6%; HR, 0.72; P <0 .001) (P = NS for interaction). The 
authors concluded that among Medicare beneficiaries 
hospitalized for heart failure and with an LVEF between 
30% and 35% and <30%, survival at 3 years was better in 
patients who received a prophylactic ICD than in 
comparable patients with no ICD (Al-Khatib et al, JAMA. 
2014;311:2209-2215).  
 
CRT-D Better than ICD in Older than 65 Years Old 
Patients 
 7090 propensity-matched patients older than 65 years 
with reduced left ventricular ejection fraction (<0.35) and 
prolonged QRS duration on electrocardiography (≥120 
ms) were treated with CRT-D or ICD implantation. At the 
3-year follow-up period, compared with ICD therapy, 
CRT-D was associated with lower risks for mortality 
(cumulative incidence, 25.7% vs 29.8%; adjusted hazard 
ratio-HR, 0.82), all-cause readmission (cumulative 
incidence, 68.6% vs 72.8%; adjusted HR, 0.86 ), 
cardiovascular readmission (cumulative incidence, 45.0% 
vs 52.4%; adjusted HR, 0.80), and heart failure 
readmission (cumulative incidence, 24.3% vs 29.4%, HR 
O.78). It was also associated with greater risks for device-
related infection (cumulative incidence, 1.9% vs 1.0%). 
The lower risks for heart failure readmission associated 
with CRT-D compared with ICD therapy were most 
pronounced among patients with left bundle branch block 
or a QRS duration at least 150 ms and in women. In older 
patients with reduced left ventricular ejection fraction and 
prolonged QRS duration, CRT-D was associated with 
lower risks for death and readmission than ICD therapy 
alone (Masoudi et al, Ann Intern Med 2014;160:603-611).  
 
Safe and Effective Transcathter Aortic Valve 
Implantation (TAVI) Using a Self-Expanding 
Bioprosthesis in Patients With Severe Aortic Stenosis 
at Very High Risk for Surgery 
 A prospective, multicenter, nonrandomized study 
evaluated the safety and efficacy of self-expanding TAVI 
in patients (n=489) with symptomatic severe aortic 
stenosis with prohibitive risks for surgery at 41 US sites. 
All-cause mortality or major stroke occurred in 26% vs 
expected 43% at 12 months (p < 0.0001). Individual 30-
day and 1-year events included all-cause mortality (8.4% 
and 24.3%, respectively) and major stroke (2.3% and 
4.3%, respectively). Procedural events at 30 days: life-
threatening bleeding (12.7%), major vascular 
complications (8.2%), and need for permanent pacemaker 
placement (21.6%). Moderate or severe paravalvular aortic 
regurgitation was lower 12 months after self-expanding 
TAVI (4.2%) than at discharge (10.7%; p = 0.004). The 
authors concluded that TAVI with a self-expanding 
bioprosthesis was safe and effective in patients with 
symptomatic severe aortic stenosis with a prohibitive risk 
for surgery (Popma et al, J Am Coll Cardiol 
2014;63:1972–1981).  
 
Transcatheter Aortic-Valve Replacement with a Self-
Expanding Prosthesis Superior to Surgery in Patients 
at Increased Surgical Risk 
 This study compared transcatheter aortic-valve 
implantation (TAVI), using a self-expanding aortic-valve 
bioprosthesis, with surgical aortic-valve replacement in 
795 patients with severe aortic stenosis and an increased 
risk of death during surgery. In the as-treated analysis, the 
rate of death from any cause at 1 year was significantly 
lower in the TAVI group than in the surgical group (14.2% 
vs 19.1%) (P<0.001 for noninferiority; P = 0.04 for 
superiority). The results were similar in the intention-to-
treat analysis. The authors concluded that in patients with 
severe aortic stenosis who are at increased surgical risk, 
TAVI compared to surgery was associated with a 
significantly higher rate of survival at 1 year (Adams et al, 
N Engl J Med 2014; 370:1790-1798).  
 
CHOICE Trial: Balloon-Expandable Superior to Self-
Expandable Valves in Patients Undergoing TAVI 
 A total of 241 patients undergoing transcatheter aortic 
valve implantation (TAVI) were randomly assigned to 
receive a balloon-expandable valve (Edwards Sapien XT) 
(n=121) or a self-expandable valve (Medtronic 
CoreValve) (n=120). Device success was 95.9% in the 
balloon-expandable valve group and 77.5% in the self-
expandable valve group (relative risk -RR, 1.24, P < .001), 
due to a significantly lower frequency of residual more-
than-mild aortic regurgitation (4.1% vs 18.3%; RR, 0.23; 
P < .001) and a less frequent need for implanting more than 
1 valve (0.8% vs 5.8%, P =0 .03) in the balloon-
expandable valve group. Cardiovascular mortality at 30 
days was comparable (4.1% vs 4.3%, RR, 0.97; P = NS), 
as well as bleeding and vascular complications. Need for a 
permanent pacemaker was less frequent in the balloon-
expandable valve group (17.3% vs 37.6%, P = 0.001). The 
authors concluded that among patients with high-risk 
aortic stenosis undergoing TAVI, the use of a balloon-
expandable valve resulted in a greater rate of device 
success than use of a self-expandable valve (Abdel-Wahab 
et al, JAMA 2014;311:1503-1514).  
 
ARISTOTLE Trial: Major Bleeding in Patients With 
Atrial Fibrillation is Less in Patients Receiving 
Apixaban than Warfarin 
 The on-treatment safety population in the ARISTOTLE 
trial included 18,140 patients. The rate of major 
hemorrhage among patients in the apixaban group was 
2.13% per year compared with 3.09% in the warfarin 
group (hazard ratio -HR 0.69; p< 0.001). The most 
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frequent sites of major hemorrhage were gastrointestinal 
(31%; n= 248), intracranial (22%; n= 171), and soft tissue 
(10%; n= 75). Compared with warfarin, apixaban-related 
major extracranial bleeding led to reduced hospitalization, 
medical or surgical intervention, transfusion, or change in 
antithrombotic therapy. Fatal major hemorrhage within 30 
days occurred half as often wiith apixaban than warfarin 
(HR 0.50; p< 0.001). Older age, prior hemorrhage, prior 
stroke or transient ischemic attack, diabetes, lower 
creatinine clearance, decreased hematocrit, aspirin 
therapy, and nonsteroidal anti-inflammatory drugs were 
independently associated with an increased risk. The 
authors conclude that apixaban, compared with warfarin, 
was associated with fewer intracranial hemorrhages, less 
adverse consequences following extracranial hemorrhage, 
and a 50% reduction in fatal hemorrhage at 30 days (Hylek 
et al, J Am Coll Cardiol 2014;63:2141-2147).  
 
MENDEL-2: Anti-PCSK9 Inhibitor Most Effective for 
Hypercholesterolemia 
 This study comprised 614 patients (18-80 years old) 
with fasting low-density lipoprotein cholesterol (LDL-C) 
>100 and <190 mg/dl and Framingham risk scores >10%, 
randomized (1:1:1:1:2:2) to oral placebo and subcutaneous 
(SC) placebo biweekly; oral placebo and SC placebo 
monthly; ezetimibe and SC placebo biweekly; ezetimibe 
and SC placebo monthly; oral placebo and evolocumab 
140 mg biweekly; or oral placebo and evolocumab 420 mg 
monthly. Evolocumab, a human monoclonal antibody 
against proprotein convertase subtilisin/kexin type 9 
(PCSK9), significantly reduced LDL-C from baseline, on 
average, by 55% to 57% more than placebo and 38% to 
40% more than ezetimibe (p < 0.001 for all). Therapy-
related adverse events (AEs), muscle-related AEs, and 
laboratory abnormalities were comparable across 
treatment groups. The authors concluded that evolocumab 
significantly reduced LDL-C compared with placebo or 
ezetimibe and was well tolerated in patients with 
hypercholesterolemia (Koren et al, J Am Coll Cardiol 
2014;63:2531–2540).  
 
GAUSS-2: Evolocumab is Promising for High-Risk 
Statin-Intolerant Hypercholesterolemic Patients  
 GAUSS-2 (Goal Achievement after Utilizing an Anti-
PCSK9 Antibody in Statin Intolerant Subjects) trial was a 
12-week, double-blind study comprising 307 patients, 
aged 62+10 years with LDL-C 193+59 mg/dl, (2:2:1:1) 
randomized to evolocumab 140 mg every 2 weeks (Q2W) 
or evolocumab 420 mg once monthly (QM) both with daily 
oral placebo or subcutaneous placebo Q2W or QM both 
with daily oral ezetimibe 10 mg. Evolocumab reduced 
LDL-C from baseline by 53-56%, differences of 37-39% 
vs ezetimibe (p <0.001). Muscle adverse events occurred 
in 12% with evolocumab vs 23% with ezetimibe. 
Treatment-related adverse events and laboratory 
abnormalities were comparable among treatment groups. 
The authors concluded that evolocumab is a promising 
therapy for high-risk patients with high cholesterol who are 
statin intolerant (Stroes et al, J Am Coll Cardiol 
2014;63:2541–2548).  
 
DESCARTES: A Successful 52-Week Placebo-
Controlled Trial of Evolocumab in Hyperlipidemia 
 A total of 901 patients with hyperlipidemia were started 
on diet alone or diet plus atorvastatin at a dose of 10 mg 
daily, atorvastatin at 80 mg daily, or atorvastatin at 80 mg 
daily plus ezetimibe at 10 mg daily, for a run-in period of 
4 to 12 weeks. Patients with an LDL cholesterol (LDL-C) 
level of >75 mg/dl were then randomly assigned in a 2:1 
ratio to receive either evolocumab (420 mg) or placebo 
every 4 weeks. Evolocumab reduced LDL-C by 
57.0±2.1% (P<0.001). Evolocumab treatment also 
significantly reduced levels of apolipoprotein B, non–
high-density lipoprotein cholesterol, lipoprotein(a), and 
triglycerides. The most common adverse events were 
nasopharyngitis, upper respiratory tract infection, 
influenza, and back pain. The authors concluded that at 52 
weeks, evolocumab added to diet alone, to low-dose 
atorvastatin, or to high-dose atorvastatin with or without 
ezetimibe significantly reduced LDL-C levels in patients 
with a range of cardiovascular risks (Blom et l, N Engl J 
Med 2014; 370:1809-1819).  
 
LEADLESS Trial: Implantation of Permanent 
Leadless Cardiac Pacemakers is Feasible and Safe 
 This study tested the safety and performance of a novel, 
self-contained leadless cardiac pacemaker in 33 patients 
(aged 77±8 years), mostly (67%) for complete AV block 
in the setting of permanent atrial fibrillation (AF). The 
implant success rate was 97% (n=32); 5 patients (15%) 
required >1 devices. One patient died after developing 
cardiac tamponade and stroke. The overall complication-
free rate was 94% (31/33). After 3 months of follow-up, 
the measures of pacing performance (sensing, impedance, 
and pacing threshold) either improved or remained stable. 
The authors concluded that a single-chamber leadless 
cardiac pacemaker is safe and feasible, representing a 
paradigm shift in cardiac pacing (Reddy et al, Circulation 
2014; 129: 1466-1471).  
 
French Registry (FAST-MI Trial): In a Real-World 
Setting, in Patients With STEMI, a Pharmaco-invasive 
strategy (Thrombolysis With Subsequent PCI) is a 
Valid Alternative to Primary PCI, with Equivalent 5-
Year Survival  
 Although primary percutaneous coronary intervention 
(pPCI) is the preferred reperfusion method for ST-
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segment-elevation myocardial infarction (STEMI), it 
remains difficult to implement. Five-year mortality was 
assessed in 1492 patients with STEMI of whom 447 (30%) 
received fibrinolysis (66% prehospital; 97% with 
subsequent angiography, 84% with subsequent PCI), 583 
(39%) had pPCI, and 462 (31%) received no reperfusion. 
Five-year survival was 88% for fibrinolysis, 83% for pPCI, 
and 59% for no reperfusion, with hazard ratios of 0.73 for 
fibrinolysis vs pPCI, 0.57 for prehospital fibrinolysis vs 
pPCI, and 0.63 for fibrinolysis vs pPCI. In propensity 
score-matched populations, survival rates were not 
significantly different for fibrinolysis and pPCI, both in the 
whole population (88% lysis, 85% pPCI) and in the 
population seen early (87% fibrinolysis, 85% pPCI beyond 
90 minutes from call). The authors concluded that in a real-
world setting, on a nationwide scale, a pharmaco-invasive 
strategy is a valid alternative to pPCI, with an equivalent 
5-year survival to that of thrombolysis (Danchin et al, 
Circulation 2014;129:1629-1636).  
 
SORT OUT III study: Superiority of Sirolimus-Eluting 
Stent at 1 year over Zotarolimus-Eluting Stent is Lost 
at 5 Years  
 A total of 2332 patients were randomly assigned to the 
zotarolimus-eluting Endeavor Sprint stent (ZES) 
(Medtronic, Santa Rosa, CA, USA) (n=1162) or the 
sirolimus-eluting Cypher Select Plus stent (SES) (Cordis, 
Johnson & Johnson, Warren, NJ, USA) (n=1170). At 5-
year follow-up, rates of major adverse cardiac events were 
similar in patients treated with both types of stents (ZES 
17% vs SES 15.6%; odds ratio-OR 1.10; p=NS). This 
finding contrasted with results for rates of major adverse 
cardiac events at 1-year follow up (zotarolimus 8% vs 
sirolimus 3.9%; OR 2.13; p<0·0001) compared with those 
at follow-up between 1 and 5 years (9% vs 11.6%; OR 
0.78; p=0.071). At 1-year follow-up, definite stent 
thrombosis was more frequent after implantation of the 
ZES (1.1%) than the SES (0.3%; OR 3.34; p=0.036), 
whereas the opposite finding was recorded for between 1 
and 5 years' follow-up (ZES 0.1% vs SES 1.8%, OR 0.05; 
p=0.003). 30% target lesion revascularisations in the ZES 
group occurred between 1 and 5 years' follow-up, whereas 
77% of those in the SES group occurred during this follow-
up period. The authors concluded that the superiority of 
SES compared with ZES at 1-year follow-up was lost after 
5 years (Maeng et al, Lancet 2014;383(9934):2047–2056).  
 
PEITHO: Fibrinolysis Prevented Hemodynamic 
Compromise but Increased Risk of Major Hemorrhage 
and Stroke in Intermediate Risk Patients for 
Pulmonary Embolism 
 Tenecteplase plus heparin was compared with placebo 
plus heparin in normotensive patients with intermediate-
risk pulmonary embolism. Of 1006 patients who 
underwent randomization, 1005 were included in the 
intention-to-treat analysis. Death or hemodynamic 
compromise occurred in 13 of 506 patients (2.6%) in the 
tenecteplase group and 28 of 499 (5.6%) in the placebo 
group (odds ratio, 0.44; P=0.02). Between randomization 
and day 7, a total of 6 patients (1.2%) in the tenecteplase 
group and 9 (1.8%) in the placebo group died (P=0.42). 
Extracranial bleeding occurred in 32 patients (6.3%) in the 
tenecteplase group and 6 patients (1.2%) in the placebo 
group (P<0.001). Stroke occurred in 12 patients (2.4%) in 
the tenecteplase group and was hemorrhagic in 10 patients; 
1 patient (0.2%) in the placebo group had a stroke, which 
was hemorrhagic (P=0.003). At 1 month, death rate was 
2.4%) in the tenecteplase group and 3.2% in the placebo 
group (P=0.42). The authors concluded that in patients 
with intermediate-risk pulmonary embolism, fibrinolysis 
prevented hemodynamic decompensation but increased 
risk of major hemorrhage and stroke (Meyer et al, N Engl 
J Med 2014; 370:1402-1411).  
 
RELAX-AHF Trial: Serelaxin is Effective in Acute 
Heart Failure Patients with Preserved Left Ventricular 
Ejection Fraction 
 RELAX-AHF randomized 1161 acute heart failure 
(AHF) patients to 48-h serelaxin (30 mg/kg/day) or 
placebo within 16 h from arrival; drug effects were 
compared between preserved (≥50%) (HFpEF) and 
reduced (<50%, HFrEF) ejection fraction heart failure. 
HFpEF was present in 26% of patients. Serelaxin induced 
a similar dyspnea relief in HFpEF vs HFrEF patients No 
differences were encountered in the effect of serelaxin on 
short- or long-term outcome between HFpEF and HFrEF 
patients regarding cardiovascular death or hospitalization 
for heart/renal failure at 2 months, cardiovascular death 
and all-cause death at 3 months. Similar safety and changes 
in biomarkers were found in both groups. The authors 
concluded that in AHF patients with HFpEF compared 
with those with HFrEF, serelaxin was well tolerated and 
effective in relieving dyspnea and had a similar effect on 
short- and long-term outcome, including survival benefit 
(Filippatos et al, Eur Heart J 2014; 35: 1041–1050).  
 
TOPCAT: Spironolactone for Heart Failure with 
Preserved Ejection Fraction  
 A total of 3445 patients with symptomatic heart failure 
and a left ventricular ejection fraction of >45% were 
assigned to receive either spironolactone (15 to 45 mg 
daily) or placebo. At a mean follow-up of 3.3 years, the 
primary outcome (composite of death from cardiovascular 
causes, aborted cardiac arrest, or hospitalization for the 
management of heart failure) occurred in 18.6% of patients 
in the spironolactone group and 20.4% 351 of patients in 
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the placebo group (hazard ratio, 0.89; P=0.14). 
Hospitalization for heart failure had a significantly lower 
incidence in the spironolactone group (12% vs 14%; 
hazard ratio, 0.83; P=0.04). Neither total deaths nor 
hospitalizations for any reason were significantly reduced 
by spironolactone. Treatment with spironolactone was 
associated with increased serum creatinine levels and a 
doubling of the rate of hyperkalemia (18.7%, vs 9.1%) but 
reduced hypokalemia. With frequent monitoring, there 
were no significant differences in the incidence of serious 
adverse events, a serum creatinine level of 3 mg/dl (265 
μmol/L) or higher, or dialysis. The authors concluded that 
in patients with heart failure and a preserved ejection 
fraction, treatment with spironolactone did not 
significantly reduce the incidence of death from 
cardiovascular causes, aborted cardiac arrest, or 
hospitalization for heart failure (Pitt et al, N Engl J Med 
2014; 370:1383-1392).  
 
Effective Combination Therapy With Statin and 
Another Agent vs Intensified Statin Monotherapy for 
Patients Intolerant of or Unresponsive to Statins 
 According to a review of 36 trials, for patients 
intolerant of or unresponsive to statins, low-intensity statin 
plus bile acid sequestrant decreased LDL cholesterol level 
0-14% more than mid-intensity monotherapy among high-
risk hyperlipidemic patients. Mid-intensity statin plus 
ezetimibe decreased LDL cholesterol level 5-15% and 3-
21% more than high-intensity monotherapy among 
patients with atherosclerotic heart disease and diabetes, 
respectively. Evidence was insufficient to evaluate LDL 
cholesterol for fibrates, niacin, and ω-3 fatty acids, or to 
assess long-term clinical outcomes, adherence, and harms 
for all regimens. The authors concluded that clinicians 
could consider using lower-intensity statin combined with 
bile acid sequestrant or ezetimibe among high-risk patients 
intolerant of or unresponsive to statins; however, this 
strategy should be used with caution given the lack of 
evidence on long-term clinical benefits or harms (Gudzune 
et al, Ann Intern Med 2014;160:468-476).  
 
CORP-2: Colchicine is Effective and Safe for 
Treatment of Multiple Recurrences of Pericarditis  
 
 Adult patients with multiple recurrences of pericarditis 
(≥2) were randomly assigned (1:1) to placebo (n=120) or 
colchicine (n=120) (0.5 mg bid for 6 months for those 
weighing >70 kg or 0.5 mg qd for weight <70 kg) in 
addition to conventional anti-inflammatory treatment with 
aspirin, ibuprofen, or indomethacin. The proportion of 
patients who had recurrent pericarditis was 21.6% in the 
colchicine group and 42.5% in the placebo group (relative 
risk 0.49; p=0·0009; number needed to treat 5). Adverse 
effects and discontinuation of study drug occurred in 
similar percentages in each group. The most common 
adverse events were gastrointestinal intolerance (9 patients 
in each group) and hepatotoxicity (3 vs 1). No serious 
adverse events were reported. The authors concluded that 
colchicine added to conventional anti-inflammatory 
treatment significantly reduced the rate of subsequent 
recurrences of pericarditis in patients with multiple 
recurrences (Imazio et al, Lancet 2014;383(9936):2232 – 
2237).  
 
Important Review and Other Articles  
 
 Obesity & cardiovascular disease (Lavie et al, J Am 
Coll Cardiol 2014;63:1345-1354), Subcutaneous 
defibrillator (Aziz et al, J Am Coll Cardiol 2014;63:1473-
1479), Coronary artery calcification (Madhavan et al, J Am 
Coll Cardiol 2014;63:1703-1714), Lone AF (Wyse et al, J 
Am Coll Cardiol 2014;63:1715-1723), Severe 
hypercholesterolemia (Sniderman et al, J Am Coll Cardiol 
2014;63:1935-1947), Percutaneous mitral valve repair 
(Feldman & Young, J Am Coll Cardiol 2014;63:2057-
2068), Micro-RNAs in cardiovascular disease (Condorelli 
et al, J Am Coll Cardiol 2014;63:2177-2187), 2014 
AHA/ACC Guideline for the management of patients with 
valvular heart disease (Nishimura et al, J Am Coll Cardiol 
2014;63:2438-2488 63 & e57-e185; Circulation 2014;129: 
2440-2492), In-stent restenosis (Alfonso et al, J Am Coll 
Cardiol 2014;63:2659-2673), Mitral regurgitation & 
TAVI (Nombela-Franco et al, J Am Coll Cardiol 
2014;63:2643-2658), 2013 ACC/AHA Guidelines for 
treating hypercholesterolemia (Stone et al, J Am Coll 
Cardiol 2014; 63:2889–934), Bicuspid aortic valve 
(Michelena et al, Circulation 2014;129:2691-2704), heart 
failure with preserved ejection fraction (Komajda & Lam, 
Eur Heart J 2014; 35: 1022-1032), Complications after 
cardiac implantable electronic device implantations 
Kirkfeldt et al, Eur Heart J 2014; 35: 1186-1194), Risk of 
proarrhythmia by psychotropic medications (Fanoe et al, 
Eur Heart J 2014; 35: 1306-1315), Depression and 
cardiovascular disease (Hare et al, Eur Heart J 
2014;35:1365-1372), HIV infection and cardiovascular 
disease (Hemkens & Bucher, Eur Heart J 2014;35: 1373-
1381), Aortic dilatation in bicuspid aortic valve (Verma & 
Siu, N Engl J Med 2014; 370:1920-1929), Cardiovascular 
remodelling (Heusch et al, Lancet 2014; 383 (9932): 1933 
– 1943).  
